NCT05252481 (STIMULATECOVID) is a NA clinical trial of Active tDCS in COVID-19, sponsored by Hospital San Carlos, Madrid.

Who is sponsoring NCT05252481?

NCT05252481 is sponsored by Hospital San Carlos, Madrid.

What drugs are being tested in NCT05252481?

Interventions in NCT05252481: Active tDCS, Sham tDCS.

Is NCT05252481 still recruiting?

NCT05252481 is currently completed. Last updated 22 August 2022.

Last reviewed 2022-08-22 · How we verify

NCT05252481: STIMULATECOVID

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Transcranial Direct Stimulation for Persistent Fatigue Treatment Post-COVID-19

Completed NA Last updated 22 August 2022

What this trial tests

NA trial testing Active tDCS in COVID-19 in 47 participants. Completed in 31 July 2022.

Timeline

1 April 2022

Primary endpoint
26 June 2022

31 July 2022

Quick facts

Lead sponsor	Hospital San Carlos, Madrid
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	47
Start date	1 April 2022
Primary completion	26 June 2022
Estimated completion	31 July 2022
Sites	1 location across Spain

Drugs / interventions tested

Active tDCS
Sham tDCS

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

Hospital San Carlos, Madrid

Who can join

18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Fatigue is common and disabling in patients with post-COVID syndrome. There is no treatment available at this moment, and fatigue has important consequences. The main aim of this study is to evaluate the changes in the severity of fatigue using non-invasive neuromodulation in patients with post-COVID condition. This is a randomized, parallel, double-blind, placebo-controlled clinical trial using transcranial direct current stimulation. Secondary aims include changes in cognition, depression, and quality of life.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Transcranial direct current stimulation for post-COVID fatigue: a randomized, double-blind, controlled pilot study.
Oliver-Mas S, Delgado-Alonso C, Delgado-Álvarez A, Díez-Cirarda M, et al · · 2023 · cited 25× · PMID 37091591 · DOI 10.1093/braincomms/fcad117
Transcranial Direct Current Stimulation (tDCS) for Post-COVID Fatigue: A Randomized, Double-Blind, Controlled Pilot Study
Oliver-Mas S, Delgado-Alonso C, Delgado-Álvarez A, Díez-Cirarda M, et al · · 2022 · DOI 10.2139/ssrn.4216601

Verify or expand the search:

Other trials of Active tDCS

Trials testing the same drug.

NCT07246993 — Targeting Neuroplasticity for Persistent Post-Concussive Cognitive Symptoms · NA · recruiting
NCT07404319 — Effectiveness of Exercise Alone and tDCS+Exercise on Cognitive Function Improvement in Patients With Treatment Resistant · NA · not yet recruiting
NCT07212829 — The Added Value of Transcranial Direct Current Stimulation (tDCS) During Exercise for People With Chronic Widespread Pai · NA · not yet recruiting
NCT07202455 — Effect of Early Neuromodulation Coupled With Rehabilitation on the Prevention of Post-stroke Pain · NA · not yet recruiting
NCT06901687 — Home-Based Transcranial Direct Current Stimulation (tDCS) for Depression in Multiple Sclerosis (MS) · Phase 2 · recruiting

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Hospital San Carlos, Madrid trials

Trials by the same sponsor.

NCT06310941 — Mechanical Insufflation-exsufflation and Hypertonic Saline in Nosocomial Bacterial Respiratory Tract Infection · NA · not yet recruiting
NCT07002658 — Clinical Impact of Surgical Wound Morbidity According to the Type of Saphenous Vein Harvesting Technique (Endoscopic vs. · NA · not yet recruiting
NCT06113939 — Prevention of Infection of the Respiratory Tract Through Application of Non-Invasive Methods of Secretion Suctioning · NA · not yet recruiting
NCT06156059 — Oral Bedtime Melatonin in Critically Ill Patients · Phase 4 · unknown
NCT07390175 — Ablation of Human Cardiac Fibrillation Based on Models of Hierarchical Organization of Tissue Excitation · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05252481 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hospital San Carlos, Madrid
Last refreshed: 22 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05252481.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing